SYGNAMAP
Map Spatial Omics For Signatures Of Cure
We Drive Change
SygnaMap leverages spatial omics and computational imaging to identify critical pathways underlying the fundamental pathologies of diseases. Complex diseases can be resolved to the key molecules that serve as biomarkers to guide therapeutic targets and monitor disease activity.
To keep up with the latest SYGNAMAP news, follow us on LinkedIn.
![iStock-638307722_EPS [Converted]-01.jpg](https://static.wixstatic.com/media/d572d5_aa3302bd82da4057b92a04e835cd309b~mv2.jpg/v1/fill/w_120,h_120,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/d572d5_aa3302bd82da4057b92a04e835cd309b~mv2.jpg)
SYGNAMAP Innovation
Precision medicine champions a patient-centric vision with therapeutic choices driven by predictive biomarkers to optimise highly effective, patient-specific therapies and reduce adverse effects. Spatial omics and imaging will revolutionize disease understanding by bringing advances in single-cell mass spectrometry technologies to identify small molecules that regulate and coordinate cellular neighborhoods.
SYGNAMAP is a highly innovative San Antonio biotech startup that is at the nexus of Spatial Omics and AI-driven Computational Pathology. Funded by multiple NIH/NSF SBIR awards, we are bringing precision medicine to reality with a patient-centric vision to enable highly effective therapies driven by specific predictive biomarkers. SygnaMap is building novel computational algorithms to map spatial omics to identify signatures of disease and develop cures for rare and common diseases.